Norveška -
norveščina -
Statens legemiddelverk
amlodipine/valsartan/hydrochlorothiazide mylan
mylan ab - amlodipinbesilat / valsartan / hydroklortiazid - tablett, filmdrasjert - 10 mg / 160 mg / 12.5 mg
Norveška -
norveščina -
Statens legemiddelverk
amlodipine/valsartan/hydrochlorothiazide mylan
mylan ab - amlodipinbesilat / valsartan / hydroklortiazid - tablett, filmdrasjert - 5 mg / 160 mg / 12.5 mg
Norveška -
norveščina -
Statens legemiddelverk
amlodipine/valsartan/hydrochlorothiazide mylan
mylan ab - amlodipinbesilat / valsartan / hydroklortiazid - tablett, filmdrasjert - 5 mg / 160 mg / 25 mg
Norveška -
norveščina -
Statens legemiddelverk
amlodipine/valsartan/hydrochlorothiazide mylan
mylan ab - amlodipinbesilat / valsartan / hydroklortiazid - tablett, filmdrasjert - 10 mg / 160 mg / 25 mg
Norveška -
norveščina -
Statens legemiddelverk
amlodipine/valsartan/hydrochlorothiazide mylan
mylan ab - amlodipinbesilat / valsartan / hydroklortiazid - tablett, filmdrasjert - 10 mg / 320 mg / 25 mg
Norveška -
norveščina -
Statens legemiddelverk
ropinirol mylan 1 mg
mylan ab - ropinirolhydroklorid - tablett, filmdrasjert - 1 mg
Norveška -
norveščina -
Statens legemiddelverk
ropinirol mylan 0.5 mg
mylan ab - ropinirolhydroklorid - tablett, filmdrasjert - 0.5 mg
Norveška -
norveščina -
Statens legemiddelverk
alendronat mylan 10 mg
mylan ab - natriumalendronattrihydrat - tablett - 10 mg
Norveška -
norveščina -
Statens legemiddelverk
ropinirol mylan 5 mg
mylan ab - ropinirolhydroklorid - tablett, filmdrasjert - 5 mg
Evropska unija -
norveščina -
EMA (European Medicines Agency)
fingolimod mylan
mylan ireland limited - fingolimod hydrochloride - multippel sklerose, relapsing-remitting - immunsuppressive - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 og 5. 1)orpatients med raskt utviklende alvorlig relapsing remitting multippel sklerose definert ved 2 eller flere deaktivere tilbakefall i ett år, og med 1 eller flere gadolinium å styrke lesjoner på brain mr eller en betydelig økning i t2 lesjon legg i forhold til en tidligere nyere mr.